38 / 86
0,0
0,2
0,4
0,6
0,8
1,0
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45
Eribulin
Dacarbazine
Eribulin Dacarbazine
Median (mos)
13.5
11.5
HR (95% CI)
0.768 (0.618-0.954)
Stratified
P
-value
0.0169
The primary endpoint of OS was met, indicating a
2-month improvement in median OS with eribulin
Eribulin 228
197 162
138
120
97
88
64
45
34
25
14
7
1
1
0
Dacarbazine
224
190 158
130
103
81
64
45
32
24
16
8
3
0
0
0
Survival Time (mos)
Patients at Risk:
1. Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
2. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37
Survival Probability